| 1 |
Development of a tri-functional bispecific antibody candidate activating Tie2 and inhibiting VEGF/Ang-2 for treating wet agerelated macular degeneration (wAMD) |
| Antibody |
Wet age-related macular degeneration (wAMD) |
Tie2, VEGF, Ang-2 |
Candidate |
MabTics Co., Ltd. |
RS-2024-00334041 |
|
| 2 |
Development of therapeutic candidate: Tie2 and Ang2 dual modulator for the next.generation treatment of wAMD and DR. |
| Antibody |
wet AMD/DR |
Ang2.targeting Tie2 receptor |
Candidate |
Neortesbio Co.,Ltd. |
RS-2023-00282960 |
|
| 3 |
Development of recombinant protein targeting human complement C5 for dry age.related macular degeneration treatment |
| Antibody |
Macular degeneration |
Human Complement C5 |
Lead |
Immunabs Co., Ltd. |
RS-2023-00282906 |
|
| 4 |
Phase 1 clinical study of first in class tie2 activator PMC.403 in patients with age.related macular degeneration |
| Antibody |
Macular degeneration |
TIE.2 |
Phase 1 |
Pharm Abcine Inc. |
RS-2023-00282791 |
|
| 5 |
Retinal regenerative antibody and gene therapy |
| Antibody |
Degenerative Retinal Disease |
PROX1 |
Hit |
CELLIAZ |
RS-2023-00258166 |
|